Fitlife Brands FTLF

NASDAQ FTLF

$9.58 -0.19 (-1.94%)

As of: Sep 9, 2026 · 2:24 PM EDT

Key Stats

Market Cap92.22 Mn

P/E14.74

P/S1.12

Div. Yield0.00

Total Debt (Qtr)35.91 Mn

Revenue Growth (1y) (Qtr)64.62

Add ratio to table…

About

FitLife Brands, Inc. is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers. The company operates in the nutrition industry, focusing on the development, marketing, and distribution of a diverse portfolio of branded products across multiple categories including sports nutrition, weight loss, general health, and specialty wellness. Its core business involves sourcing, formulating, and selling products through…

FitLife Brands, Inc. generates revenue primarily through the sale of its nutritional supplement and wellness products to end consumers and wholesale partners. The company markets its products under multiple brand families, including NDS Products, iSatori Products, MRC Products, MusclePharm Products, and Irwin Products, each targeting specific consumer segments. Revenue is derived from distribution through franchised General Nutrition Centers stores, specialty and mass market retailers, online platforms such as Amazon, and direct-to-consumer channels via company-owned websites. The company also leverages wholesale partnerships with major retailers to expand market reach and drive sales volume across its product lines.

FitLife Brands, Inc. operates through the following segments: NDS Products, iSatori Products, MRC Products, MusclePharm Products, and Irwin Products.

NDS Products: This segment includes brands such as NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition. These products are positioned as premium weight loss, sports nutrition, and general health offerings with an emphasis on natural, vegan, and organic ingredients in certain lines. The NDS Products are distributed principally through franchised General Nutrition Centers stores located both domestically and internationally, with additional distribution through corporate GNC stores in the United States.
iSatori Products: This segment consists of the Energize, iSatori, and BioGenetic Laboratories brands. Energize focuses on energy-boosting formulations using time-released caffeine, vitamins, and herbal ingredients, while iSatori and BioGenetic Laboratories offer weight loss and sports nutrition products at varying price points. These products are sold through retail locations including specialty and mass market stores, as well as online directly to consumers via the company’s websites and e-commerce platforms such as Amazon, with major customers including Vitamin Shoppe and Walgreens.
MRC Products: This segment includes the Dr. Tobias, All Natural Advice, and Maritime Naturals brands, which were acquired through the purchase of MRC in February 2023. Dr. Tobias offers general health supplements, while All Natural Advice and Maritime Naturals specialize in natural skincare and beauty products that are registered with Health Canada and compliant with the EU Cosmetics Act. The MRC Products are distributed primarily through Amazon, as well as through the company’s own websites and other e-commerce platforms, targeting consumers seeking natural wellness and personal care solutions.
MusclePharm Products: This segment encompasses the MusclePharm brand, acquired by the company on October 10, 2023. MusclePharm is a scientifically driven performance lifestyle brand that develops, markets, and distributes sports nutrition and general health products. Its offerings are sold to wholesale customers as well as online directly to end consumers through company-owned websites and e-commerce platforms including Amazon, leveraging strong brand recognition among athletes and active individuals to drive engagement and repeat purchases.
Irwin Products: This segment comprises the Irwin Naturals, Applied Nutrition, and Nature’s Secret brands, acquired by the company on August 8, 2025. Irwin Naturals focuses on high-potency, bioavailable supplements for targeted nutrition categories, Applied Nutrition emphasizes weight loss, cleansing, and sexual health, and Nature’s Secret promotes total body wellness. These products are sold principally through wholesale channels in mass market and health food store segments, with major customers including CVS, Walmart, Walgreens, and Costco Canada, and are also distributed online directly to consumers through the company’s e-commerce platforms.

FitLife Brands, Inc. competes in a highly fragmented and competitive nutrition industry where numerous players offer similar products in sports nutrition, weight loss, and general wellness categories. The company differentiates itself through its multi-brand strategy, proprietary formulations, and focus on innovation, quality, and functional ingredients. While many competitors possess greater financial and operational resources, FitLife Brands leverages its agility, targeted brand positioning, and ability to respond quickly to market trends and consumer demands to maintain relevance and drive growth in niche segments.

FitLife Brands, Inc. serves a diverse customer base that includes health-conscious consumers, athletes, fitness enthusiasts, and individuals seeking preventive health and wellness solutions. The company sells its products through franchised General Nutrition Centers locations, specialty retailers such as Vitamin Shoppe, mass market retailers including CVS, Walmart, and Walgreens, and online platforms like Amazon. Specific wholesale customers for the Irwin Products segment include CVS, Walmart, Walgreens, and Costco Canada, while iSatori Products are distributed through Vitamin Shoppe and Walgreens. The company also reaches end consumers directly through its own websites and various e-commerce channels across all brand families.

Investment Thesis

▲ Bull case

FitLife is positioned to unlock significant margin expansion through Irwin's supply chain improvements, particularly by transitioning to 3-year shelf life dating on slow-moving softgel products, which historically required discarding approximately $2 million of obsolete inventory annually. This initiative directly addresses Irwin's biggest operational inefficiency—high MOQs combined with short selling windows—by extending the sell-through period from 12 to 24 months, reducing write-offs and lowering cost of goods sold. Management confirmed that early production runs with updated formulas and 3-year dating have already begun arriving, with impact expected to flow through the P&L starting in Q2 FY26. Beyond inventory savings, the shift enables better inventory timing, reduces stockout risks from delayed replenishment, and aligns with Irwin's growing online sales channel, which faces less stringent shelf-life requirements. The CFO noted that achieving 300–400 basis points of gross margin improvement at Irwin would meaningfully lift consolidated margins toward the high 30s, especially as legacy FitLife stabilizes in the low 40s. This operational fix is not merely incremental but structural, targeting a multi-year drag on profitability that prior ownership failed to address due to complexity and resource constraints. The combination of formula reformulation, manufacturer coordination, and testing rigor underscores a deep commitment to sustainable margin recovery, with tangible benefits expected to compound as more SKUs transition throughout 2026.
Irwin's Amazon business represents a high-potential, underappreciated growth engine that is already scaling rapidly despite broader macro headwinds, with monthly revenue rising from ~$0.5 million at Q4 FY25 year-end to ~$0.8 million in early Q1 FY26—implying a $9–10 million annual run rate and strong subscriber growth from 500 to over 3,600 since January 2026. This trajectory is driven by strategic off-Amazon demand generation, particularly through TikTok and influencer partnerships (e.g., Joey Chestnut for Dr. Tobias), which management explicitly linked to improved Amazon performance via algorithmic shifts favoring external traffic. The company highlighted that its most successful Amazon accounts (like Irwin) correlate directly with highest off-platform distribution, reversing the prior reliance on on-platform advertising alone. Crucially, Irwin still has numerous wholesale-distributed SKUs not yet live on Amazon due to third-party testing requirements, and there is untapped potential in Amazon Canada, where Irwin’s products are Health Canada-registered but not yet sold. These factors suggest the current online run rate understates true potential, especially as stockout issues for high-moving SKUs resolve with improved supply chain discipline. The persistence of subscriber growth post-Algorithm shift (A9 to A10) indicates genuine organic traction, not pandemic-era pull-forward, and the CMO-led centralization of marketing efforts signals a long-term shift toward sustainable, profitable customer acquisition.
Despite near-term weakness in legacy brands, FitLife’s strategic initiatives are creating a virtuous cycle where improved supply chain resilience at Irwin enables more reliable wholesale distribution, which in turn supports cross-selling of legacy brands like MusclePharm into regional grocery chains—a process already yielding early wins with 6 MusclePharm SKUs placed in a regional chain beginning Q2 FY26. Management emphasized that wholesale planogram resets occur only once or twice yearly, meaning placement gains are lagging indicators of deeper retail relationships being rebuilt. This effort is bolstered by Irwin’s strengthened sales force, now able to leverage its established wholesale footprint to introduce complementary FitLife products, a tactic historically underutilized due to Irwin’s prior financial distress. Simultaneously, SG&A efficiencies are being pursued through lease right-sizing (e.g., Irwin’s LA office lease renewal at lower cost) and historical MRC office exit, reflecting disciplined cost control without compromising growth investments. These actions collectively de-risk the turnaround by lowering fixed costs while enhancing revenue quality—focusing on margin-accretive wholesale and online channels rather than chasing low-margin volume. The company’s deliberate avoidance of formal guidance underscores confidence in internal levers over macro forecasts, preferring to let operational progress speak for itself. With debt reduction ahead of schedule ($1.9M paid in Q4 FY25, plus additional amortizations) and free cash flow being directed to deleveraging, the balance sheet is improving independently of earnings volatility, creating optionality for future reinvestment or returns should stabilization occur sooner than expected.

FitLife is positioned to unlock significant margin expansion through Irwin's supply chain improvements, particularly by transitioning to 3-year shelf life dating on slow-moving softgel products, which historically required discarding approximately $2 million of obsolete inventory annually. This initiative directly addresses Irwin's biggest operational inefficiency—high MOQs combined with short selling windows—by extending the sell-through period from 12 to 24 months, reducing write-offs and lowering cost of goods sold. Management confirmed that early production runs with updated formulas and 3-year dating have already begun arriving, with impact expected to flow through the P&L starting in Q2 FY26. Beyond inventory savings, the shift enables better inventory timing, reduces stockout risks from delayed replenishment, and aligns with Irwin's growing online sales channel, which faces less stringent shelf-life requirements. The CFO noted that achieving 300–400 basis points of gross margin improvement at Irwin would meaningfully lift consolidated margins toward the high 30s, especially as legacy FitLife stabilizes in the low 40s. This operational fix is not merely incremental but structural, targeting a multi-year drag on profitability that prior ownership failed to address due to complexity and resource constraints. The combination of formula reformulation, manufacturer coordination, and testing rigor underscores a deep commitment to sustainable margin recovery, with tangible benefits expected to compound as more SKUs transition throughout 2026.
Irwin's Amazon business represents a high-potential, underappreciated growth engine that is already scaling rapidly despite broader macro headwinds, with monthly revenue rising from ~$0.5 million at Q4 FY25 year-end to ~$0.8 million in early Q1 FY26—implying a $9–10 million annual run rate and strong subscriber growth from 500 to over 3,600 since January 2026. This trajectory is driven by strategic off-Amazon demand generation, particularly through TikTok and influencer partnerships (e.g., Joey Chestnut for Dr. Tobias), which management explicitly linked to improved Amazon performance via algorithmic shifts favoring external traffic. The company highlighted that its most successful Amazon accounts (like Irwin) correlate directly with highest off-platform distribution, reversing the prior reliance on on-platform advertising alone. Crucially, Irwin still has numerous wholesale-distributed SKUs not yet live on Amazon due to third-party testing requirements, and there is untapped potential in Amazon Canada, where Irwin’s products are Health Canada-registered but not yet sold. These factors suggest the current online run rate understates true potential, especially as stockout issues for high-moving SKUs resolve with improved supply chain discipline. The persistence of subscriber growth post-Algorithm shift (A9 to A10) indicates genuine organic traction, not pandemic-era pull-forward, and the CMO-led centralization of marketing efforts signals a long-term shift toward sustainable, profitable customer acquisition.
Despite near-term weakness in legacy brands, FitLife’s strategic initiatives are creating a virtuous cycle where improved supply chain resilience at Irwin enables more reliable wholesale distribution, which in turn supports cross-selling of legacy brands like MusclePharm into regional grocery chains—a process already yielding early wins with 6 MusclePharm SKUs placed in a regional chain beginning Q2 FY26. Management emphasized that wholesale planogram resets occur only once or twice yearly, meaning placement gains are lagging indicators of deeper retail relationships being rebuilt. This effort is bolstered by Irwin’s strengthened sales force, now able to leverage its established wholesale footprint to introduce complementary FitLife products, a tactic historically underutilized due to Irwin’s prior financial distress. Simultaneously, SG&A efficiencies are being pursued through lease right-sizing (e.g., Irwin’s LA office lease renewal at lower cost) and historical MRC office exit, reflecting disciplined cost control without compromising growth investments. These actions collectively de-risk the turnaround by lowering fixed costs while enhancing revenue quality—focusing on margin-accretive wholesale and online channels rather than chasing low-margin volume. The company’s deliberate avoidance of formal guidance underscores confidence in internal levers over macro forecasts, preferring to let operational progress speak for itself. With debt reduction ahead of schedule ($1.9M paid in Q4 FY25, plus additional amortizations) and free cash flow being directed to deleveraging, the balance sheet is improving independently of earnings volatility, creating optionality for future reinvestment or returns should stabilization occur sooner than expected.

▼ Bear case

FitLife’s core legacy brands continue to deteriorate under persistent macroeconomic headwinds, with total legacy FitLife revenue declining 12% year-over-year in Q4 FY25—driven by 10% lower online and 14% lower wholesale sales—despite management’s attempts to isolate weakness to MRC and MusclePharm. The CFO acknowledged broad-based consumer confidence near all-time lows and declining discretionary spending for four years straight, yet offered no concrete evidence that legacy brands excluding MRC/MusclePharm are insulated from these trends, instead citing only 4% organic growth in Q4 FY25 for the remainder—a figure that may be flattered by lapping weak prior-period comparisons or temporary wholesale restocking effects (e.g., GNC DC replenishment in Q1 FY25). Crucially, management admitted they cannot disentangle whether revenue softship stems from macro conditions or company-specific issues like out-of-stocks, and their reliance on POS data—which they described as “not always perfectly up to date”—limits visibility into true demand trends. The absence of meaningful legacy brand growth beyond marginal improvements in non-problematic segments suggests structural challenges in product relevance, channel diversification, or brand equity that acquisitions like Irwin cannot offset indefinitely, especially as online growth at Irwin remains a small fraction of total revenue (~40% of Irwin’s Q4 FY25 sales, or ~5% of consolidated revenue).
Irwin’s turnaround hinges on uncertain and delayed supply chain fixes, particularly the transition to 3-year shelf life dating, which management acknowledged requires reformulating nearly every product, securing manufacturer buy-in, and conducting extensive stability testing—a process they admitted is “not easy” and involves “lots and lots of people spending lots and lots of hours.” While early 3Y-dated products have begun arriving, the full impact on reducing the $2M annual inventory obsolescence charge is not expected until Q2 FY26 at the earliest, with no guarantee that formula adjustments will maintain efficacy or consumer acceptance over the extended shelf life. Furthermore, the company’s historical inability to resolve this issue prior to acquisition—despite knowing it was a “biggest challenge”—raises questions about whether operational complexity or cost barriers will persist, and the CFO’s admission that Irwin’s legacy gross margins were merely in the “low 30%” (not even reaching 35%) casts doubt on whether even successful remediation can reach the “high 30s” target without sustained execution risk. The emphasis on long-term effort (“this is not something that will happen next quarter”) combined with vague timelines (“hopefully in Q2 and beyond”) suggests investors may be overestimating the speed and certainty of margin recovery, particularly given that Irwin’s wholesale channel (89% of its Q4 FY25 revenue) remains vulnerable to retailer demands for minimum shelf life, which could undermine the benefits of extended dating if logistical delays persist.
FitLife’s growth strategy remains overly dependent on Irwin’s Amazon channel, which, while showing strong subscriber growth (500 to 3,600+ since Jan 2026), is still nascent and faces significant headwinds from evolving platform algorithms (A9 to A10 shift) that prioritize external traffic—a dynamic the company concedes is a “black box” and difficult to influence predictably. Management’s reliance on off-Amazon efforts like TikTok and influencer marketing (e.g., Joey Chestnut partnership) to drive Amazon sales introduces execution risk, as these channels are unproven at scale for supplement brands and subject to rapid shifts in consumer engagement and platform policies. The fact that Irwin’s Amazon growth slowed sequentially from December (~$600K) to February (~$700K) and is projected at only ~$800K for March indicates diminishing returns on early momentum, and the continued out-of-stock status of high-moving wholesale SKUs on Amazon—due to prioritizing major retail customers—creates a self-limiting loop where online growth is constrained by the very wholesale success the company seeks to leverage. Moreover, Irwin’s online channel remains low-margin relative to legacy FitLife, with adjusted gross margin of 33.2% in Q4 FY25 (vs. legacy’s 40.7%), meaning that even successful online scaling may dilute overall profitability unless offset by wholesale margin expansion—a prospect that remains unproven and contingent on resolving deep-rooted supply chain and product relevance issues.

FitLife’s core legacy brands continue to deteriorate under persistent macroeconomic headwinds, with total legacy FitLife revenue declining 12% year-over-year in Q4 FY25—driven by 10% lower online and 14% lower wholesale sales—despite management’s attempts to isolate weakness to MRC and MusclePharm. The CFO acknowledged broad-based consumer confidence near all-time lows and declining discretionary spending for four years straight, yet offered no concrete evidence that legacy brands excluding MRC/MusclePharm are insulated from these trends, instead citing only 4% organic growth in Q4 FY25 for the remainder—a figure that may be flattered by lapping weak prior-period comparisons or temporary wholesale restocking effects (e.g., GNC DC replenishment in Q1 FY25). Crucially, management admitted they cannot disentangle whether revenue softship stems from macro conditions or company-specific issues like out-of-stocks, and their reliance on POS data—which they described as “not always perfectly up to date”—limits visibility into true demand trends. The absence of meaningful legacy brand growth beyond marginal improvements in non-problematic segments suggests structural challenges in product relevance, channel diversification, or brand equity that acquisitions like Irwin cannot offset indefinitely, especially as online growth at Irwin remains a small fraction of total revenue (~40% of Irwin’s Q4 FY25 sales, or ~5% of consolidated revenue).
Irwin’s turnaround hinges on uncertain and delayed supply chain fixes, particularly the transition to 3-year shelf life dating, which management acknowledged requires reformulating nearly every product, securing manufacturer buy-in, and conducting extensive stability testing—a process they admitted is “not easy” and involves “lots and lots of people spending lots and lots of hours.” While early 3Y-dated products have begun arriving, the full impact on reducing the $2M annual inventory obsolescence charge is not expected until Q2 FY26 at the earliest, with no guarantee that formula adjustments will maintain efficacy or consumer acceptance over the extended shelf life. Furthermore, the company’s historical inability to resolve this issue prior to acquisition—despite knowing it was a “biggest challenge”—raises questions about whether operational complexity or cost barriers will persist, and the CFO’s admission that Irwin’s legacy gross margins were merely in the “low 30%” (not even reaching 35%) casts doubt on whether even successful remediation can reach the “high 30s” target without sustained execution risk. The emphasis on long-term effort (“this is not something that will happen next quarter”) combined with vague timelines (“hopefully in Q2 and beyond”) suggests investors may be overestimating the speed and certainty of margin recovery, particularly given that Irwin’s wholesale channel (89% of its Q4 FY25 revenue) remains vulnerable to retailer demands for minimum shelf life, which could undermine the benefits of extended dating if logistical delays persist.
FitLife’s growth strategy remains overly dependent on Irwin’s Amazon channel, which, while showing strong subscriber growth (500 to 3,600+ since Jan 2026), is still nascent and faces significant headwinds from evolving platform algorithms (A9 to A10 shift) that prioritize external traffic—a dynamic the company concedes is a “black box” and difficult to influence predictably. Management’s reliance on off-Amazon efforts like TikTok and influencer marketing (e.g., Joey Chestnut partnership) to drive Amazon sales introduces execution risk, as these channels are unproven at scale for supplement brands and subject to rapid shifts in consumer engagement and platform policies. The fact that Irwin’s Amazon growth slowed sequentially from December (~$600K) to February (~$700K) and is projected at only ~$800K for March indicates diminishing returns on early momentum, and the continued out-of-stock status of high-moving wholesale SKUs on Amazon—due to prioritizing major retail customers—creates a self-limiting loop where online growth is constrained by the very wholesale success the company seeks to leverage. Moreover, Irwin’s online channel remains low-margin relative to legacy FitLife, with adjusted gross margin of 33.2% in Q4 FY25 (vs. legacy’s 40.7%), meaning that even successful online scaling may dilute overall profitability unless offset by wholesale margin expansion—a prospect that remains unproven and contingent on resolving deep-rooted supply chain and product relevance issues.

Geographical Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Personal Care Products

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	CL	Colgate Palmolive Co	primary	70.76 Bn	32.83	3.36	7.86 Bn
2	KVUE	Kenvue Inc.	primary	35.95 Bn	21.68	2.33	8.48 Bn
3	KMB	Kimberly Clark Corp	primary	34.91 Bn	19.64	2.11	6.52 Bn
4	BBWI	Bath & Body Works, Inc.	primary	3.94 Bn	6.37	0.53	3.86 Bn
5	PBH	Prestige Consumer Healthcare Inc.	primary	2.94 Bn	-	-	0.99 Bn
6	PRGO	PERRIGO Co plc	primary	2.07 Bn	-1.20	0.50	3.38 Bn
7	EPC	EDGEWELL PERSONAL CARE Co	primary	1.33 Bn	-19.21	0.59	1.28 Bn
8	HLF	Herbalife Ltd.	primary	1.30 Bn	5.09	0.25	2.02 Bn

Fitlife Brands FTLF

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password